Eva C. Guinan, MD

Eva C. Guinan, MD

Pediatric Hematology/Oncology

Biography

Eva C. Guinan, MD

Dr. Guinan received her MD from Harvard Medical School in 1980, followed by a pediatric residency at Children's Hospital and a pediatric hematology-oncology fellowship at Children's Hospital and DFCI. She was appointed associate director of the Bone Marrow Transplant Service in 1990 and directed the program from 1997 through 2005. She assumed a new position in 2005 as the Associate Director of the Center for Clinical and Translational Research. Her own translational research program focuses on the costimulatory blockade as a mechanism of overcoming problems related to allogenicity in transplantation and the amelioration of regimen-related toxicity.

Researcher

Physician

Physician
Professor of Radiation Oncology, Harvard Medical School

Clinical Interests

Aplastic anemia, Bone marrow failure disorders, Hematopoietic stem cell transplantation, Myelodysplasia, Regimen-related toxicity

Board Certification

  • Pediatric Hematology/Oncology, 2004
  • Pediatrics, 1986

Fellowship

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology

Residency

  • Boston Children's Hospital

Medical School

  • Harvard Medical School

Recent Awards

  • Clare and Richard Morse Research Award 2000
  • Clinical Translational Scientist Award, Burroughs Wellcome 1999
  • Distinguished Service Award from the Fanconi Anemia Research Foundation 2009

Research

    Induction of Anergy by Costimulatory Blockade

    Our research focuses on overcoming problems related to allogenicity in transplantation. Allogeneic transplantation is limited, in large part, by the ability to find donors of suitable histocompatibility. Global immunosuppression has been an incomplete and highly toxic approach to this problem. Current understanding of T cell activation suggests that blocking B7-CD28 interactions of the costimulatory pathway for human T helper cells may provide both antigen-specific T cell hyporesponsiveness and active suppression of alloantigen specific immunity. We are applying these various strategies to the transplant setting and investigating other approaches to improve immunity after transplantation. Another area of active investigation is the mitigation of regimen-related toxicity during transplantation and/or chemotherapy. We are investigating novel agents for prevention or treatment of regimen-related toxicity, with a focus on mitigating radiation toxicity. In another area of investigation, we are examining the role of distributed problem-solving techniques in generating, evaluating and maintaining innovation in healthcare related research.

    Research Departments

    Publications

      • Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE Study consortium pilot trial. Am J Transplant. 2023 Dec; 23(12):1872-1881. View in: Pubmed

      • Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases. Transplant Cell Ther. 2023 02; 29(2):125.e1-125.e9. View in: Pubmed

      • Physical Therapists in Oncology Settings: Experiences in Delivering Cancer Rehabilitation Services, Barriers to Care, and Service Development Needs. Phys Ther. 2022 03 01; 102(3). View in: Pubmed

      • Conservatism Gets Funded? A Field Experiment on the Role of Negative Information in Novel Project Evaluation. Manage Sci. 2022 Jun; 68(6):4478-4495. View in: Pubmed

      • Ex vivo generation of regulatory T cells from liver transplant recipients using costimulation blockade. Am J Transplant. 2022 02; 22(2):504-518. View in: Pubmed

      • Engineering serendipity: When does knowledge sharing lead to knowledge production? Strateg Manag J. 2021 Jun; 42(6):1215-1244. View in: Pubmed

      • Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet. 2020 05 23; 395(10237):1627-1639. View in: Pubmed

      • Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biol Blood Marrow Transplant. 2020 02; 26(2):333-342. View in: Pubmed

      • Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 12; 25(12):2398-2407. View in: Pubmed

      • Use of Crowd Innovation to Develop an Artificial Intelligence-Based Solution for Radiation Therapy Targeting. JAMA Oncol. 2019 May 01; 5(5):654-661. View in: Pubmed

      • Alloanergization Method for Inducing Allospecific Hyporesponsiveness in PBMC Exposed to Allostimulation In Vitro in the Context of Costimulatory Molecule Blockade. Methods Mol Biol. 2019; 1899:103-118. View in: Pubmed

      • Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model. Pediatr Blood Cancer. 2019 01; 66(1):e27460. View in: Pubmed

      • Toward a more scientific science. Science. 2018 09 21; 361(6408):1194-1197. View in: Pubmed

      • The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data. NPJ Schizophr. 2018 Jun 27; 4(1):14. View in: Pubmed

      • Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clin Cancer Res. 2018 09 01; 24(17):4098-4109. View in: Pubmed

      • rBPI21 (Opebacan) Promotes Rapid Trilineage Hematopoietic Recovery in a Murine Model of High-Dose Total Body Irradiation. Am J Hematol. 2018 May 11. View in: Pubmed

      • Amelioration of Head and Neck Radiation-Induced Mucositis and Distant Marrow Suppression in Fanca-/- and Fancg-/- Mice by Intraoral Administration of GS-Nitroxide (JP4-039). Radiat Res. 2018 06; 189(6):560-578. View in: Pubmed

      • The views of patients with metastatic prostate cancer towards physical activity: a qualitative exploration. Support Care Cancer. 2018 Jun; 26(6):1747-1754. View in: Pubmed

      • A Field Experiment on Search Costs and the Formation of Scientific Collaborations. Rev Econ Stat. 2017 10; 99(4):565-576. View in: Pubmed

      • Physical activity and advanced cancer: the views of oncology and palliative care physicians in Ireland. Ir J Med Sci. 2018 May; 187(2):337-342. View in: Pubmed

      • Stepwise Distributed Open Innovation Contests for Software Development: Acceleration of Genome-Wide Association Analysis. Gigascience. 2017 05 01; 6(5):1-10. View in: Pubmed

      • Three sides to a story: Child, parent, and nurse perspectives on the child's experience during hematopoietic stem cell transplantation. Cancer. 2017 Aug 15; 123(16):3159-3166. View in: Pubmed

      • Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. Blood. 2017 04 20; 129(16):2308-2315. View in: Pubmed

      • Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study. Bone Marrow Transplant. 2017 Feb; 52(2):270-278. View in: Pubmed

      • Ex Vivo Costimulatory Blockade to Generate Regulatory T Cells From Patients Awaiting Kidney Transplantation. Am J Transplant. 2016 07; 16(7):2187-95. View in: Pubmed

      • Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65. View in: Pubmed

      • Intraoral Mitochondrial-Targeted GS-Nitroxide, JP4-039, Radioprotects Normal Tissue in Tumor-Bearing Radiosensitive Fancd2(-/-) (C57BL/6) Mice. Radiat Res. 2016 Feb; 185(2):134-50. View in: Pubmed

      • Looking Across and Looking Beyond the Knowledge Frontier: Intellectual Distance, Novelty, and Resource Allocation in Science. Manage Sci. 2016 Oct; 62(10):2765-2783. View in: Pubmed

      • Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation. F1000Res. 2015; 4:1480. View in: Pubmed

      • Poly(A)-specific ribonuclease (PARN) mediates 3'-end maturation of the telomerase RNA component. Nat Genet. 2015 Dec; 47(12):1482-8. View in: Pubmed

      • Parent Outlook: How Parents View the Road Ahead as They Embark on Hematopoietic Stem Cell Transplantation for Their Child. Biol Blood Marrow Transplant. 2016 Jan; 22(1):104-11. View in: Pubmed

      • The impact of pediatric blood and marrow transplant on parents: introduction of the parent impact scale. Health Qual Life Outcomes. 2015 Apr 09; 13:46. View in: Pubmed

      • Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation. Pediatr Blood Cancer. 2015 Apr; 62(4):687-92. View in: Pubmed

      • Changing factors associated with parent activation after pediatric hematopoietic stem cell transplant. Support Care Cancer. 2015 Jul; 23(7):1997-2006. View in: Pubmed

      • Aplastic anemia in adolescents and young adults. Acta Haematol. 2014; 132(3-4):331-9. View in: Pubmed

      • Serum citrulline as a biomarker of gastrointestinal function during hematopoietic cell transplantation in children. J Pediatr Gastroenterol Nutr. 2014 Jun; 58(6):709-14. View in: Pubmed

      • Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014 Sep; 134(3):560-567.e4. View in: Pubmed

      • Calculating the costs of an 8-week, physiotherapy-led exercise intervention in deconditioned cancer survivors in the early survivorship period (the PEACH trial). Physiotherapy. 2014 Jun; 100(2):182-4. View in: Pubmed

      • Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells. Am J Transplant. 2014 Feb; 14(2):305-18. View in: Pubmed

      • Identification of single nucleotide polymorphisms in hematopoietic cell transplant patients affecting early recognition of, and response to, endotoxin. Innate Immun. 2014 Oct; 20(7):697-711. View in: Pubmed

      • Feasibility and efficacy of a supervised exercise intervention in de-conditioned cancer survivors during the early survivorship phase: the PEACH trial. J Cancer Surviv. 2013 Dec; 7(4):551-62. View in: Pubmed

      • Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. J Clin Oncol. 2013 May 01; 31(13):1669-76. View in: Pubmed

      • Experiments in Open Innovation at Harvard Medical School: What happens when an elite academic institution starts to rethink how research gets done? MIT Sloan Manag Rev. 2013; 54(3):45-52. View in: Pubmed

      • The effect of aerobic exercise on metabolic and inflammatory markers in breast cancer survivors--a pilot study. Support Care Cancer. 2013 Jul; 21(7):1983-92. View in: Pubmed

      • Prize-based contests can provide solutions to computational biology problems. Nat Biotechnol. 2013 Feb; 31(2):108-11. View in: Pubmed

      • A young adult with aplastic anemia and gray hair. Clin Chem. 2013 Jan; 59(1):47-50. View in: Pubmed

      • Effect of weight on outcomes of children undergoing hematopoietic cell transplantation. Pediatr Hematol Oncol. 2013 Mar; 30(2):116-30. View in: Pubmed

      • Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. J Pediatric Infect Dis Soc. 2012 Jun; 1(2):103-11. View in: Pubmed

      • Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation. Cell Transplant. 2012; 21(9):2047-61. View in: Pubmed

      • Attenuation of resting energy expenditure following hematopoietic SCT in children. Bone Marrow Transplant. 2012 Oct; 47(10):1301-6. View in: Pubmed

      • Effect of titrated parenteral nutrition on body composition after allogeneic hematopoietic stem cell transplantation in children: a double-blind, randomized, multicenter trial. Am J Clin Nutr. 2012 Feb; 95(2):342-51. View in: Pubmed

      • Factors associated with parental activation in pediatric hematopoietic stem cell transplant. Med Care Res Rev. 2012 Apr; 69(2):194-214. View in: Pubmed

      • Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med. 2011 Nov 23; 3(110):110ra118. View in: Pubmed

      • Deficient expression of bactericidal/permeability-increasing protein in immunocompromised hosts: translational potential of replacement therapy. Biochem Soc Trans. 2011 Aug; 39(4):994-9. View in: Pubmed

      • 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J Leukoc Biol. 2011 Sep; 90(3):459-70. View in: Pubmed

      • Sweet syndrome in patients with Fanconi anaemia: association with extracutaneous manifestations and progression of haematological disease. Br J Haematol. 2011 Jul; 154(2):278-81. View in: Pubmed

      • Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade. J Vis Exp. 2011 Mar 14; (49). View in: Pubmed

      • Outcome of hematopoietic stem cell transplant in children with congenital heart disease. Pediatr Transplant. 2011 Feb; 15(1):75-80. View in: Pubmed

      • Diagnosis and management of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:76-81. View in: Pubmed

      • Therapy for aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:82-3. View in: Pubmed

      • Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res. 2010 May 15; 70(10):3915-24. View in: Pubmed

      • Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1005-17. View in: Pubmed

      • A multi-center, randomized, controlled trial of parenteral nutrition titrated to resting energy expenditure in children undergoing hematopoietic stem cell transplantation ("PNTREE"): rationale and design. Contemp Clin Trials. 2010 Mar; 31(2):157-64. View in: Pubmed

      • Preservation of immune repertoire by selective depletion of haploidentical grafts. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S68-74. View in: Pubmed

      • Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation. Sci Transl Med. 2009 Oct 07; 1(1):1ra3. View in: Pubmed

      • Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010 Feb; 16(2):157-68. View in: Pubmed

      • Acquired aplastic anemia in childhood. Hematol Oncol Clin North Am. 2009 Apr; 23(2):171-91. View in: Pubmed

      • Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity. Transplantation. 2008 Sep 27; 86(6):854-64. View in: Pubmed

      • Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood. 2008 Nov 15; 112(10):4318-27. View in: Pubmed

      • Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood. 2008 Sep 15; 112(6):2232-41. View in: Pubmed

      • Weekly measurements accurately represent trends in resting energy expenditure in children undergoing hematopoietic stem cell transplantation. JPEN J Parenter Enteral Nutr. 2008 Jul-Aug; 32(4):427-32. View in: Pubmed

      • Prognostic factors in the resumption of oral dietary intake after allogeneic hematopoietic stem cell transplantation (HSCT) in children. JPEN J Parenter Enteral Nutr. 2007 Jul-Aug; 31(4):295-301. View in: Pubmed

      • An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol. 2007 Feb; 136(4):549-64. View in: Pubmed

      • Antigen-specific T-lymphocyte function after cord blood transplantation. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1335-42. View in: Pubmed

      • Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):919-27. View in: Pubmed

      • A novel pattern of transaminase elevation associated with autologous transplant for neuroblastoma. Pediatr Transplant. 2006 Sep; 10(6):669-76. View in: Pubmed

      • Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplant. 2006 Jan; 37(1):73-80. View in: Pubmed

      • Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Sep; 11(9):721-31. View in: Pubmed

      • Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood. 2005 Sep 01; 106(5):1749-54. View in: Pubmed

      • Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94. View in: Pubmed

      • Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Mar; 11(3):213-22. View in: Pubmed

      • Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005 Mar; 11(3):261-2. View in: Pubmed

      • Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol. 2005 Jan; 128(2):221-3. View in: Pubmed

      • Aplastic anemia: management of pediatric patients. Hematology Am Soc Hematol Educ Program. 2005; 104-9. View in: Pubmed

      • Dyskeratosis congenita vs. chronic graft versus host disease: report of a case and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Nov; 98(5):566-71. View in: Pubmed

      • Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation. Br J Haematol. 2004 Nov; 127(3):322-5. View in: Pubmed

      • Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood. Bone Marrow Transplant. 2004 Nov; 34(9):795-8. View in: Pubmed

      • A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2004 Sep; 10(9):635-44. View in: Pubmed

      • Endotoxemia and elevation of lipopolysaccharide-binding protein after hematopoietic stem cell transplantation. Pediatr Infect Dis J. 2003 Nov; 22(11):978-81. View in: Pubmed

      • Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003 Dec 15; 102(13):4567-75. View in: Pubmed

      • Homozygous alpha-thalassemia treated with intrauterine transfusions and postnatal hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003 Aug; 32(3):341-2. View in: Pubmed

      • Changes in resting energy expenditure among children undergoing allogeneic stem cell transplantation. Am J Clin Nutr. 2003 Jul; 78(1):104-9. View in: Pubmed

      • Waiting for organ transplantation: results of an analysis by an Institute of Medicine Committee. Biostatistics. 2003 Apr; 4(2):207-22. View in: Pubmed

      • Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003 Feb 15; 75(3):389-97. View in: Pubmed

      • Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood. 2003 Feb 01; 101(3):831-6. View in: Pubmed

      • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100(13):4337-43. View in: Pubmed

      • Neutrophil defense in patients undergoing bone marrow transplantation: bactericidal/permeability-increasing protein (BPI) and defensins in graft-derived neutrophils. Transplantation. 2002 May 15; 73(9):1522-6. View in: Pubmed

      • Marrow failure. Hematology Am Soc Hematol Educ Program. 2002; 58-72. View in: Pubmed

      • Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol. 2001; 106(1-2):57-68. View in: Pubmed

      • Impact of pharmacy practices on the cost of colony-stimulating factor use in pediatric stem cell transplantation: an institution-based analysis. J Pediatr Hematol Oncol. 2001 Jan; 23(1):19-24. View in: Pubmed

      • Balancing efficacy with cost: antiemetic control in the pediatric stem cell transplant (SCT) population. Bone Marrow Transplant. 2000 Mar; 25(5):553-7. View in: Pubmed

      • The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol. 1999 Dec; 107(3):485-93. View in: Pubmed

      • Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999 Jun 03; 340(22):1704-14. View in: Pubmed

      • Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes. Br J Haematol. 1998 Nov; 103(2):304-7. View in: Pubmed

      • Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant. 1998 Oct; 22(8):735-41. View in: Pubmed

      • Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44. View in: Pubmed

      • Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer. Mol Med. 1998 Jul; 4(7):468-79. View in: Pubmed

      • Clinical aspects of aplastic anemia. Hematol Oncol Clin North Am. 1997 Dec; 11(6):1025-44. View in: Pubmed

      • Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 1997 Nov; 20(9):737-43. View in: Pubmed

      • Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate. J Reprod Med. 1997 Sep; 42(9):537-41. View in: Pubmed

      • Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. Bone Marrow Transplant. 1997 Aug; 20(3):257-60. View in: Pubmed

      • Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant. 1997 Jul; 20(1):33-8. View in: Pubmed

      • High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997 Jun; 3(2):98-106. View in: Pubmed

      • Isolated testicular relapse in an adolescent 5 years following allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 1997 Apr; 19(8):849-51. View in: Pubmed

      • Measurement of plasma busulfan concentration by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit. 1997 Apr; 19(2):169-74. View in: Pubmed

      • Bone marrow transplantation in sickle cell anemia--the dilemma of choice. N Engl J Med. 1996 Aug 08; 335(6):426-8. View in: Pubmed

      • Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1149-55. View in: Pubmed

      • Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood. 1996 Jun 01; 87(11):4887-93. View in: Pubmed

      • Long-term follow-up of 12 pediatric patients with primary myelodysplastic syndrome treated with HLA-identical sibling donor bone marrow transplantation. Blood. 1996 May 01; 87(9):4020-2. View in: Pubmed

      • Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood. 1996 Apr 01; 87(7):3012-8. View in: Pubmed

      • Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore). 1996 Mar; 75(2):77-8. View in: Pubmed

      • GM-CSF clinical trials: pediatric aplastic anemia and Fanconi's anemia. Pediatr Nurs. 1995 Jul-Aug; 21(4):345-9. View in: Pubmed

      • Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994 Nov 15; 84(10):3261-82. View in: Pubmed

      • Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 1994 Aug 15; 84(4):1342-8. View in: Pubmed

      • Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation. 1994 Mar 15; 57(5):677-84. View in: Pubmed

      • Evaluation of granulocyte-macrophage colony-stimulating factor for treatment of pancytopenia in children with fanconi anemia. J Pediatr. 1994 Jan; 124(1):144-50. View in: Pubmed

      • In vitro enhancement of erythropoiesis by steel factor in Diamond-Blackfan anemia and treatment of other congenital cytopenias with recombinant interleukin 3/granulocyte-macrophage colony stimulating factor. Stem Cells. 1993 Jul; 11 Suppl 2:113-22. View in: Pubmed

      • Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol. 1993 Jun; 11(6):1085-91. View in: Pubmed

      • Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood. 1993 Apr 01; 81(7):1691-8. View in: Pubmed

      • Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991 Oct 15; 78(8):2139-49. View in: Pubmed

      • Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol. 1990 Oct; 8(10):1707-14. View in: Pubmed

      • A phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor for children with aplastic anemia. Blood. 1990 Sep 15; 76(6):1077-82. View in: Pubmed

      • Renal insufficiency after total body irradiation for pediatric bone marrow transplantation. Radiother Oncol. 1990; 18 Suppl 1:139-42. View in: Pubmed

      • Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease. Prog Clin Biol Res. 1990; 333:207-15. View in: Pubmed

      • Bone marrow transplantation for children with myelodysplastic syndromes. Blood. 1989 Feb; 73(2):619-22. View in: Pubmed

      • Vascular endothelial cells enhance T cell responses by markedly augmenting IL-2 concentrations. Cell Immunol. 1989 Jan; 118(1):166-77. View in: Pubmed

      • Cytoplasmic transfer between endothelium and lymphocytes: quantitation by flow cytometry. Am J Pathol. 1988 Sep; 132(3):406-9. View in: Pubmed

      • Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood. 1988 Aug; 72(2):451-5. View in: Pubmed

      • Late onset of renal dysfunction in survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):99-104. View in: Pubmed

      • Bone marrow transplantation for constitutional pure red cell aplasia. Blood. 1988 Jan; 71(1):226-9. View in: Pubmed

      • Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986 Nov; 68(5):1114-8. View in: Pubmed

      • Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol. 1986 Apr; 123(1):16-24. View in: Pubmed

      • Efficacy of a cyclophosphamide-procarbazine-antithymocyte serum regimen for prevention of graft rejection following bone marrow transplantation for transfused patients with aplastic anemia. Transplantation. 1985 Jun; 39(6):671-3. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Smith 339A Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Smith 339A Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Eva C. Guinan, MD

      About Our Ratings

      Physician Star Rating Comment Block

      Discovery and Insights